GLYCO-IMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer
GLYCO-IMMUNE CHECKPOINT INHIBITORS
The Need
Despite the early success of first-generation immuno-oncology drugs, most cancer patients still do not achieve clinical responses.
The Scientific Opportunity
Cell surface glycosylation is now known to play a central role in immuno-oncology: Tumor cells evolve over time, cloaking themselves in certain glycan patterns that down-regulate a wide spectrum of innate and adaptive immune cell types which are critical to fighting cancer.
The Approach
Palleon Pharmaceuticals has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glyco-Immune Checkpoint Inhibitors to treat cancer patients.
News
Palleon Pharmaceuticals Appoints Lori Hu of Vertex Ventures HC to Board of Directors
December 12, 2017Palleon Pharmaceuticals Signs Exclusive License Agreement with King’s College London for Intellectual Property Related to Glycoimmune Checkpoints to Treat Cancer
Twitter
@Palleon_Pharma
Our HYDRA platform is a proprietary patient stratification technology, which enables the selection of patients who… http://3WvsRaX8Oz
@Palleon_Pharma
Today, Palleon's CEO Jim Broderick will speak @LSXLeaders World Congress on the Fast Growers panel, where he and ot… http://70Fx5L5sZB